المؤلفون: Stéphane deBotton, Joseph M. Brandwein, Andrew H. Wei, Arnaud Pigneux, Bruno Quesnel, Xavier Thomas, Ollivier Legrand, Christian Recher, Sylvain Chantepie, Mathilde Hunault‐Berger, Nicolas Boissel, Salem A. Nehme, Mark G. Frattini, Alessandra Tosolini, Roland Marion‐Gallois, Jixian J. Wang, Chris Cameron, Muhaimen Siddiqui, Brian Hutton, Gary Milkovich, Eytan M. Stein

المصدر: Cancer Medicine, Vol 10, Iss 18, Pp 6336-6343 (2021)

مصطلحات موضوعية: acute myeloid leukemia, enasidenib, IDH2 mutations, overall survival, standard of care, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/a8b6b60e03224a14a77e3d31e872ffc8Test

المؤلفون: Dona Ann Johns, Richard Williams, Craig M Smith, Pavani P Nadaminti, Rasika Samarasinghe

مصطلحات موضوعية: Health sciences, Nursing, Science & Technology, Life Sciences & Biomedicine, Oncology, Medicine, Research & Experimental, Research & Experimental Medicine, epigenetics, gliomas, methylation, paediatric astrocytoma, INTRINSIC PONTINE GLIOMA, CENTRAL-NERVOUS-SYSTEM, HIGH-GRADE GLIOMAS, CONVENTIONAL RADIATION-THERAPY, BRAIN-TUMORS, MOLECULAR-GENETICS, IDH2 MUTATIONS, HISTONE H3.3, CHILDREN, EFFICACY

العلاقة: http://hdl.handle.net/10779/DRO/DU:25149047.v3Test; https://figshare.com/articles/journal_contribution/Novel_insights_on_genetics_and_epigenetics_as_clinical_targets_for_paediatric_astrocytoma/25149047Test

الإتاحة: http://hdl.handle.net/10779/DRO/DU:25149047.v3Test
https://figshare.com/articles/journal_contribution/Novel_insights_on_genetics_and_epigenetics_as_clinical_targets_for_paediatric_astrocytoma/25149047Test

المؤلفون: D. Matsko E., M. Matsko V., A. Baksheeva O., E. Imyanitov N., A. Ulitin Yu., V. Moiseenko M., K. Shelekhova V., N. Volkov M., A. Ievleva G., V. Tiurin I., S. Sklyar S., A. Zrelov A., A. Morozova S., Д. Мацко Е., М. Мацко В., А. Бакшеева О., Е. Имянитов Н., А. Улитин Ю., В. Моисеенко М., К. Шелехова В., Н. Волков М., А. Иевлева Г., В. Тюрин И., С. Скляр С., А. Зрелов А., А. Морозова С.

المساهمون: Работа выполнена при поддержке гранта РФФИ 18-315-00437

المصدر: Siberian journal of oncology; Том 20, № 6 (2021); 55-68 ; Сибирский онкологический журнал; Том 20, № 6 (2021); 55-68 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-6

مصطلحات موضوعية: glioblastoma, astrocytoma, intratumor heterogeneity, morphologic heterogeneity, moleculargenetic heterogeneity, gene expression, IDH1 and IDH2 mutations, глиобластома, анапластическая астроцитома, внутриопухолевая гетерогенность, морфологическая гетерогенность, молекулярно-генетическая гетерогенность, экспрессия генов, мутации в генах IDH1 и IDH2

وصف الملف: application/pdf

العلاقة: https://www.siboncoj.ru/jour/article/view/1985/931Test; Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. Nutr Rev. 1989 Jan; 47(1): 23–5. doi:10.1111/j.1753-4887.1989.tb02747.x.; Strauss Y., Globus J. Spongioblastoma with unusually rapid growth following decompression. Neurol. Bull. 1918; 1: 273–279.; Земская А.Г. Мультиформные глиобластомы головного мозга. Л., 1976. 178 с.; Смирнов Л.И. Морфология нервной системы, общая нормальная и патологическая гистология. М., 1935. 256 с.; Гейманович А.И., Смирнова Л.И. Опухоли центральной нервной системы. Гос. мед. издат. УССР, 1936; С. 401–421.; Васкин И.С., Васильев А.А. Патогистологическая характеристика опухолей центральной нервной системы. Современная хирургия. 1934; 6: 506–526.; Савенко С.Н. Мультиформная спонгиобластома. Опухоли центральной нервной системы. 1936; С. 424–443.; Scherer H., Gliomstudien. I.I. Uber die Grenzen der Zelldiagnostik der Gehirngeschwulsten, gargestellt am Beispiel des «Glioblastoma multiforme ganglioides. Virchow s, Arch. 1935; 294: 795–822.; Scherer H. The forms of growth in gliomas and their practical significance. Brain. 1940; 63: 11–35.; Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10; 352(10): 997–1003. doi:10.1056/NEJMoa043331.; Chinot O.L., Barrié M., Fuentes S., Eudes N., Lancelot S., Metellus P., Muracciole X., Braguer D., Ouafik L., Martin P.M., Dufour H., Figarella-Branger D. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007 Apr 20; 25(12): 1470–5. doi:10.1200/JCO.2006.07.4807.; Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009 Apr; 174(4): 1149–53. doi:10.2353/ajpath.2009.080958.; Kim Y.H., Nobusawa S., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Vital A., Mariani L., Stawski R., Watanabe T., De Girolami U., Kleihues P., Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010 Dec; 177(6): 2708–14. doi:10.2353/ajpath.2010.100680.; Labussière M., Idbaih A., Wang X.W., Marie Y., Boisselier B., Falet C., Paris S., Laffaire J., Carpentier C., Crinière E., Ducray F., El Hallani S., Mokhtari K., Hoang-Xuan K., Delattre J.Y., Sanson M. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010; 74(23): 1886–90. doi:10.1212/WNL.0b013e3181e1cf3a.; Kim Y.H., Nobusawa S., Mittelbronn M., Paulus W., Brokinkel B. Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Vital A., Mariani L., Stawski R., Watanabe T., De Girolami U., Kleihues P., Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010 Dec; 177(6): 2708–14. doi:10.2353/ajpath.2010.100680.; Hartmann C., Hentschel B., Tatagiba M., Schramm J., Schnell O., Seidel C., Stein R., Reifenberger G., Pietsch T., von Deimling A., Loeffler M., Weller M. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011; 17(13): 4588–99. doi:10.1158/1078-0432.CCR-10-3194.; Meyer M., Reimand J., Lan X., Head R., Zhu X., Kushida M., Bayani J., Pressey J.C., Lionel A.C., Clarke I.D., Cusimano M., Squire J.A., Scherer S.W., Bernstein M., Woodin M.A., Bader G.D., Dirks P.B. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015; 112(3): 851–6. doi:10.1073/pnas.1320611111.; Parker N.R., Hudson A.L., Khong P., Parkinson J.F., Dwight T., Ikin R.J., Zhu Y., Cheng Z.J., Vafaee F., Chen J., Wheeler H.R., Howell V.M. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016 Mar 4; 6: 22477. doi:10.1038/srep22477.; Qazi M.A., Vora P., Venugopal C., Sidhu S.S., Moffat J., Swanton C., Singh S.K. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017 Jul 1; 28(7): 1448–56. doi:10.1093/annonc/mdx169.; Juillerat-Jeanneret L., Bernasconi C.C., Bricod C., Gros S., Trepey S., Benhattar J., Janzer R.C. Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest. 2008 Jul; 26(6): 597–609. doi:10.1080/07357900802072913.; Hamilton M.G., Roldán G., Magliocco A., McIntyre J.B., Parney I., Easaw J.C. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol. 2011 Apr; 102(2): 255–60. doi:10.1007/s11060-010-0307-5.; Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N., Ivantsov A.O., Togo A.V., Polyakov I.S., Orlov S.V., Matsko D.E., Novik V.I., Imyanitov E.N. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013 Jul; 121(7): 370–6. doi:10.1002/cncy.21281.; Журид И.С. К учению о спонгиобластомах. Сборник, посвященный 30-летию деятельности С.Н. Давиденкова. 1936; С. 193–194.; Маньковский Б.Н., Савенко С.Н. О корреляции клиники и структуры глиом. Советская психоневрология. 1937; 8: 43–49.; Ротенберг С.И. К характеристике мультиформных спонгиобластом. Труды II Всесоюзного съезда невропатологов и психиатров. T. IV. 1937; 331–355.; Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23; 455(7216): 1061–8. doi:10.1038/nature07385.; Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., Asthana S., Jalbert L.E., Nelson S.J., Bollen A.W., Gustafson W.C., Charron E., Weiss W.A., Smirnov I.V., Song J.S., Olshen A.B., Cha S., Zhao Y., Moore R.A., Mungall A.J., Jones S.J.M., Hirst M., Marra M.A., Saito N., Aburatani H., Mukasa A., Berger M.S., Chang S.M., Taylor B.S., Costello J.F. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10; 343(6167): 189–193. doi:10.1126/science.1239947.; Yip S., Miao J., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L., Louis D.N. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009 Jul 15; 15(14): 4622–9. doi:10.1158/1078-0432.CCR-08-3012.; Little S.E., Popov S., Jury A., Bax D.A., Doey L., Al-Sarraj S., Jurgensmeier J.M., Jones C. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 2012 Apr 1; 72(7): 1614–20. doi:10.1158/0008-5472.CAN-11-4069.; Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013 Mar 5; 110(10): 4009–14. doi:10.1073/pnas.1219747110.; Soeda A., Hara A., Kunisada T., Yoshimura S., Iwama T., Park D.M. The evidence of glioblastoma heterogeneity. Sci Rep. 2015 Jan 27; 5: 7979. doi:10.1038/srep07979.; Reinartz R., Wang S., Kebir S., Silver D.J., Wieland A., Zheng T., Küpper M., Rauschenbach L., Fimmers R., Shepherd T.M., Trageser D., Till A., Schäfer N., Glas M., Hillmer A.M., Cichon S., Smith A.A., Pietsch T., Liu Y., Reynolds B.A., Yachnis A., Pincus D.W., Simon M., Brüstle O., Steindler D.A., Scheffler B. Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Clin Cancer Res. 2017 Jan 15; 23(2): 562–574. doi:10.1158/1078-0432.CCR-15-2089.; Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8): 765–73. doi:10.1056/NEJMoa0808710.; Parkinson J.F., Wheeler H.R., Clarkson A., McKenzie C.A., Biggs M.T., Little N.S., Cook R.J., Messina M., Robinson B.G., McDonald K.L. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol. 2008 Mar; 87(1): 71–8. doi:10.1007/s11060-007-9486-0.; Cao V.T., Jung T.Y., Jung S., Jin S.G., Moon K.S., Kim I.Y., Kang S.S., Park C.S., Lee K.H., Chae H.J. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009 Nov; 65(5): 866–75; discussion 875. doi:10.1227/01.NEU.0000357325.90347.A1.; Akgül S., Patch A.M., D’Souza R.C.J., Mukhopadhyay P., Nones K., Kempe S., Kazakoff S.H., Jeffree R.L., Stringer B.W., Pearson J.V., Waddell N., Day B.W. Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. Cancers (Basel). 2019; 11(2): 190. doi:10.3390/cancers11020190.; Lemée J.M., Clavreul A., Menei P. Intratumoral heterogeneity in glioblastoma: don’t forget the peritumoral brain zone. Neuro Oncol. 2015 Oct; 17(10): 1322–32. doi:10.1093/neuonc/nov119.; Parker N.R., Khong P., Parkinson J.F., Howell V.M., Wheeler H.R. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015 Mar 3; 5: 55. doi:10.3389/fonc.2015.00055.; Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003 Dec 9; 100(25): 15178–83. doi:10.1073/pnas.2036535100.; Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003 Sep 15; 63(18): 5821–8.; Ding Y., Hubert C.G., Herman J., Corrin P., Toledo C.M., SkuttKakaria K., Vazquez J., Basom R., Zhang B., Risler J.K., Pollard S.M., Nam D.H., Delrow J.J., Zhu J., Lee J., DeLuca J., Olson J.M., Paddison P.J. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov. 2013 Feb; 3(2): 198–211. doi:10.1158/2159-8290.CD-12-0353.; Herman J.A., Toledo C.M., Olson J.M., DeLuca J.G., Paddison P.J. Molecular pathways: regulation and targeting of kinetochore-microtubule attachment in cancer. Clin Cancer Res. 2015 Jan 15; 21(2): 233–9. doi:10.1158/1078-0432.CCR-13-0645.; Lee E., Pain M., Wang H., Herman J.A., Toledo C.M., DeLuca J.G., Yong R.L., Paddison P., Zhu J. Sensitivity to BUB1B Inhibition Defines an Alternative Classification of Glioblastoma. Cancer Res. 2017; 77(20): 5518–5529. doi:10.1158/0008-5472.CAN-17-0736.; Berghoff A.S., Kiesel B., Widhalm G., Rajky O., Ricken G., Wöhrer A., Dieckmann K., Filipits M., Brandstetter A., Weller M., Kurscheid S., Hegi M.E., Zielinski C.C., Marosi C., Hainfellner J.A., Preusser M., Wick W. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015 Aug; 17(8): 1064–75. doi:10.1093/neuonc/nou307.; Yang I., Tihan T., Han S.J., Wrensch M.R., Wiencke J., Sughrue M.E., Parsa A.T. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010 Nov; 17(11): 1381–5. doi:10.1016/j.jocn.2010.03.031.; Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3): 261–79. doi:10.1215/15228517-2006-008.; Donson A.M., Birks D.K., Schittone S.A., KleinschmidtDeMasters B.K., Sun D.Y., Hemenway M.F., Handler M.H., Waziri A.E., Wang M., Foreman N.K. Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. J Immunol. 2012 Aug 15; 189(4): 1920–7. doi:10.4049/jimmunol.1103373.; Li B., Severson E., Pignon J.C., Zhao H., Li T., Novak J., Jiang P., Shen H., Aster J.C., Rodig S., Signoretti S., Liu J.S., Liu X.S. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016 Aug 22; 17(1): 174. doi:10.1186/s13059-016-1028-7.; Huang B., Zhang H., Gu L., Ye B., Jian Z., Stary C., Xiong X. Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res. 2017; 2017: 3597613. doi:10.1155/2017/3597613.; Daniel P.M., Filiz G., Tymms M.J., Ramsay R.G., Kaye A.H., Stylli S.S., Mantamadiotis T. Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures. Exp Mol Pathol. 2018 Aug; 105(1): 23–31. doi:10.1016/j.yexmp.2018.05.009.; Neftel C., Laffy J., Filbin M.G., Hara T., Shore M.E., Rahme G.J., Richman A.R., Silverbush D., Shaw M.L., Hebert C.M., Dewitt J., Gritsch S., Perez E.M., Gonzalez Castro L.N., Lan X., Druck N., Rodman C., Dionne D., Kaplan A., Bertalan M.S., Small J., Pelton K., Becker S., Bonal D., Nguyen Q.D., Servis R.L., Fung J.M., Mylvaganam R., Mayr L., Gojo J., Haberler C., Geyeregger R., Czech T., Slavc I., Nahed B.V., Curry W.T., Carter B.S., Wakimoto H., Brastianos P.K., Batchelor T.T., StemmerRachamimov A., Martinez-Lage M., Frosch M.P., Stamenkovic I., Riggi N., Rheinbay E., Monje M., Rozenblatt-Rosen O., Cahill D.P., Patel A.P., Hunter T., Verma I.M., Ligon K.L., Louis D.N., Regev A., Bernstein B.E., Tirosh I., Suvà M.L. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 Aug 8; 178(4): 835–849.e21. doi:10.1016/j.cell.2019.06.024.; Wenger A., Ferreyra Vega S., Kling T., Bontell T.O., Jakola A.S., Carén H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol. 2019 May 6; 21(5): 616–627. doi:10.1093/neuonc/noz011.; Pang L., Hu J., Li F., Yuan H., Yan M., Liao G., Xu L., Pang B., Ping Y., Xiao Y., Li X. Discovering Rare Genes Contributing to Cancer Stemness and Invasive Potential by GBM Single-Cell Transcriptional Analysis. Cancers (Basel). 2019 Dec 16; 11(12): 2025. doi:10.3390/cancers11122025.; Lee E., Yong R.L., Paddison P., Zhu J. Comparison of glioblastoma (GBM) molecular classification methods. Semin Cancer Biol. 2018 Dec; 53: 201–211. doi:10.1016/j.semcancer.2018.07.006.; https://www.siboncoj.ru/jour/article/view/1985Test

الإتاحة: https://doi.org/10.21294/1814-4861-2021-20-6-55-68Test
https://doi.org/10.21294/1814-4861-2021-20-6Test
https://doi.org/10.1111/j.1753-4887.1989.tb02747.xTest
https://doi.org/10.1056/NEJMoa043331Test
https://doi.org/10.1200/JCO.2006.07.4807Test
https://doi.org/10.2353/ajpath.2009.080958Test
https://doi.org/10.2353/ajpath.2010.100680Test
https://doi.org/10.1212/WNL.0b013e3181e1cf3aTest
https://doi.org/10.1073/pnas.1320611111Test
https://doi.org/10.1038/srep22477Test

المؤلفون: Oh, Sehyun, Cho, Youngup, Chang, Minsun, Park, Sunghyouk, Kwon, Hyuk Nam

المساهمون: Molecular and Integrative Biosciences Research Programme, Kidney development, Mitochondrial Morphogenesis

مصطلحات موضوعية: metformin, metabolomics, 2-HG, PHGDH, anticancer effect, ONCOMETABOLITE 2-HYDROXYGLUTARATE, IDH2 MUTATIONS, INHIBITOR, ACCUMULATION, CONTRIBUTES, PERSPECTIVE, HOMEOSTASIS, METABOLISM, BIGUANIDES, PREVENTION, 3122 Cancers, 3111 Biomedicine

وصف الملف: application/pdf

العلاقة: This research was funded by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Korean government (MSIT) (NRF-2014M3A9B6069340).; Oh , S , Cho , Y , Chang , M , Park , S & Kwon , H N 2021 , ' Metformin Decreases 2-HG Production through the MYC-PHGDH Pathway in Suppressing Breast Cancer Cell Proliferation ' , Metabolites , vol. 11 , no. 8 , 480 . https://doi.org/10.3390/metabo11080480Test; 85111639044; 13e9d995-7ea8-4114-b8bb-c737c7d3fc38; http://hdl.handle.net/10138/337894Test; 000689632700001

الإتاحة: http://hdl.handle.net/10138/337894Test

المؤلفون: Virijevic Marijana, Karan-Djurasevic Teodora, Marjanovic Irena, Tosic Natasa, Mitrovic Mirjana, Djunic Irena, Colovic Natasa, Vidovic Ana, Suvajdzic-Vukovic Nada, Tomin Dragica, Pavlovic Sonja

المصدر: Radiology and Oncology, Vol 50, Iss 4, Pp 385-393 (2016)

مصطلحات موضوعية: idh1 mutations, idh2 mutations, acute myeloid leukaemia, normal karyotype, Medical physics. Medical radiology. Nuclear medicine, R895-920

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1581-3207Test

الوصول الحر: https://doaj.org/article/037e7a0e54c243be9b819d16a572a371Test

المؤلفون: Wilpshaar, Tessa AH, Bovée, Judith VMG

المساهمون: Dept of Pathology, Leiden University Medical Center, P.O Box 9600 2300 RC Leiden, The Netherlands

مصطلحات موضوعية: Enchondroma, IDH1 mutations, IDH2 mutations, Tumors Section

العلاقة: Atlas of Genetics and Cytogenetics in Oncology and Haematology; http://AtlasGeneticsOncology.org/Tumors/EnchondromaID5333.htmlTest; Tessa AH, Wilpshaar; Judith VMG, Bovée. Bone: Enchondroma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, 4, p. 101-104; http://hdl.handle.net/2042/70187Test; https://doi.org/10.4267/2042/70187Test

الإتاحة: https://doi.org/10.4267/2042/70187Test
http://hdl.handle.net/2042/70187Test

المؤلفون: Venneker, S.

المساهمون: Bovée, J.V.M.G., Danen, E.H.J., Szuhai, K., Jager, M.J., Sys, G., Desar, I.M.E., Jacobs, J.J.L., Leiden University

المصدر: None

مصطلحات موضوعية: 3D cell culture, Bone tumour, H3F3A mutation, PARP inhibition, Chondrosarcoma, IDH1 and IDH2 mutations, Sarcoma, HDAC inhibition, Giant cell tumour of bone

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::73ccd68bd906aec7b9362218623409bcTest
http://hdl.handle.net/1887/3505433Test

المؤلفون: D. E. Matsko, M. V. Matsko, A. O. Baksheeva, E. N. Imyanitov, A. Yu. Ulitin, V. M. Moiseenko, K. V. Shelekhova, N. M. Volkov, A. G. Ievleva, V. I. Tiurin, S. S. Sklyar, A. A. Zrelov, A. S. Morozova

المصدر: Sibirskij Onkologičeskij Žurnal, Vol 20, Iss 6, Pp 55-68 (2022)

مصطلحات موضوعية: Cancer Research, Oncology, morphologic heterogeneity, glioblastoma, gene expression, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, intratumor heterogeneity, astrocytoma, moleculargenetic heterogeneity, RC254-282, idh1 and idh2 mutations

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f5a08ca78cd6fd50e4efb277a7e17dTest
https://www.siboncoj.ru/jour/article/view/1985Test

المؤلفون: Picca, Alberto, Berzero, Giulia, Di Stefano, Anna Luisa, Sanson, Marc

المساهمون: Università degli Studi di Pavia = University of Pavia (UNIPV), Hôpital Foch Suresnes, Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

المصدر: ISSN: 1473-7159.

مصطلحات موضوعية: IDH1and IDH2 mutations, gliomagenesis, grade II and III gliomas, biomarkers, target therapy, [SDV]Life Sciences [q-bio], [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30427756; hal-01971809; https://hal.sorbonne-universite.fr/hal-01971809Test; https://hal.sorbonne-universite.fr/hal-01971809/documentTest; https://hal.sorbonne-universite.fr/hal-01971809/file/Picca%202018%20IDH1-IDH2_sans%20marque.pdfTest; PUBMED: 30427756

الإتاحة: https://doi.org/10.1080/14737159.2018.1548935Test
https://hal.sorbonne-universite.fr/hal-01971809Test
https://hal.sorbonne-universite.fr/hal-01971809/documentTest
https://hal.sorbonne-universite.fr/hal-01971809/file/Picca%202018%20IDH1-IDH2_sans%20marque.pdfTest

المؤلفون: van den Bent, Martin J, Baumert, Brigitta, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Baurain, Jean Francais, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Brachman, David G, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Weber, Damien C, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Pascoe, Sarah, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, van Heuvel, Irene, Stupp, Roger, Aldape, Ken, Jenkins, Robert B, Dubbink, Hendrikus Jan, Dinjens, Winand N M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, Wick, Wolfgang, Kros, Johan M

المصدر: van den Bent , M J , Baumert , B , Erridge , S C , Vogelbaum , M A , Nowak , A K , Sanson , M , Brandes , A A , Clement , P M , Baurain , J F , Mason , W P , Wheeler , H , Chinot , O L , Gill , S , Griffin , M , Brachman , D G , Taal , W , Rudà , R , Weller , M , McBain , C , Reijneveld , J , Enting , R H , Weber , ....

مصطلحات موضوعية: BRAIN-TUMOR GROUP, LOW-GRADE GLIOMA, EUROPEAN ORGANIZATION, OLIGODENDROGLIAL TUMORS, IDH2 MUTATIONS, III TRIAL, PROCARBAZINE, VINCRISTINE, GLIOBLASTOMA, CHEMOTHERAPY

العلاقة: https://research.rug.nl/en/publications/e0a08e12-2ea9-4561-be22-0764dde6546eTest

الإتاحة: https://doi.org/10.1016/S0140-6736Test(17)31442-3
https://hdl.handle.net/11370/e0a08e12-2ea9-4561-be22-0764dde6546eTest
https://research.rug.nl/en/publications/e0a08e12-2ea9-4561-be22-0764dde6546eTest
https://www.zora.uzh.ch/id/eprint/141071/1/catnon_manuscript_lancetv_3rd_revision_final.pdfTest